» Articles » PMID: 24270746

Retrospective Analysis of the Effect of Angiotensin II Receptor Blocker Versus β-blocker on Aortic Root Growth in Paediatric Patients with Marfan Syndrome

Overview
Journal Heart
Date 2013 Nov 26
PMID 24270746
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Cardiovascular pathology, including aortic root dilation at the level of sinus of Valsalva (SV), is one of the major causes of morbidity in paediatric patients with Marfan syndrome (MFS). β-Blocker (BB) is well established to slow aortic dilation in MFS. Less is known about the effectiveness of angiotensin II receptor blocker (ARB) on aortic dilation in paediatric patients with MFS.

Methods: 215 patients with MFS (9.01 ± 5.7 years) were subject to a standardised diagnostic programme. Aortic root dilation was evaluated and followed up by echocardiography. In 48 cases, BB and ARB effects on aortic root dilation were evaluated. Effect of treatment was measured by comparison of z scores of SV before and after treatment initiation.

Results: Treatment by ARB and BB leads to significant reduction of SV dilation (p<0.05). The deviation of SV enlargement from normal as expressed by the rate of change in z scores was significantly reduced by a mean difference of -0.56 ± 0.71 z scores (p<0.001) under ARB therapy and by a mean difference of -0.35 ± 0.68 z scores (p<0.05) under BB therapy. The prophylactic effect of ARB and BB on aortic root dilation is similar in both groups (p>0.05).

Conclusions: Both concepts lead to a significant reduction of SV dilation. The effect of ARB and BB is similar. This is the first study concerning the comparison of ARB and BB in previously untreated paediatric patients with MFS. The results of the study show that both treatment strategies are beneficial in paediatric and adolescent patients.

Citing Articles

Management of aortic disease in children with FBN1-related Marfan syndrome.

Muino-Mosquera L, Cervi E, De Groote K, Dewals W, Fejzic Z, Kazamia K Eur Heart J. 2024; 45(39):4156-4169.

PMID: 39250726 PMC: 11472455. DOI: 10.1093/eurheartj/ehae526.


TGFβ level in healthy and children with Marfan syndrome-effective reduction under sartan therapy.

Stark V, Olfe J, Diaz-Gil D, von Kodolitsch Y, Kozlik-Feldmann R, Reincke J Front Pediatr. 2024; 12:1276215.

PMID: 38379908 PMC: 10877724. DOI: 10.3389/fped.2024.1276215.


Prophylactic effect of angiotensin receptor blockers in children with genetic aortopathies: the early bird catches the worm.

Olfe J, Kanitz J, Stark V, Stute F, von Kodolitsch Y, Biermann D Clin Res Cardiol. 2023; 112(11):1610-1619.

PMID: 37160466 PMC: 10584712. DOI: 10.1007/s00392-023-02221-4.


Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.

Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L Lancet. 2022; 400(10355):822-831.

PMID: 36049495 PMC: 7613630. DOI: 10.1016/S0140-6736(22)01534-3.


Ascending aorta curvature and flow displacement are associated with accelerated aortic growth at long-term follow-up: A MRI study in Marfan and thoracic aortic aneurysm patients.

van Hout M, Juffermans J, Lamb H, Kroner E, van den Boogaard P, Schalij M Int J Cardiol Heart Vasc. 2022; 38:100926.

PMID: 34977327 PMC: 8683588. DOI: 10.1016/j.ijcha.2021.100926.